enVVeno Medical regains Nasdaq compliance; reports about $28 million in cash
enVVeno Medical said Nasdaq notified it that the company regained compliance with the $1.00 minimum bid price rule and that the matter is closed. The company also reported cash and investments of approximately $28 million as of December 31, 2025. The filing does not include revenue, net loss, or guidance, and the company says it expects to share more details on its 2026 strategic plans in the coming weeks.
- Nasdaq confirmed the closing bid price was at or above $1.00 for 10 consecutive business days, from January 20, 2026 through February 2, 2026.
- Cash and investments were approximately $28 million as of December 31, 2025.
- The company expects to share additional details on its 2026 strategic plans in the coming weeks.